IRDNasdaqPharmaceutical PreparationsUS GAAP · USD

Opus Genetics, Inc.

Opus Genetics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and other ophthalmic disorders. Its pipeline includes AAV-based gene therapy programs, a small-molecule ophthalmic candidate, and a licensed eye-drop product that generates royalty revenue through a partner.

Kysy yhtiöstä
Liikevaihto14,2milj. USD
+29,1 %v/v
Liikevoitto (EBIT)−38,6milj. USD
+37,8 %v/v
EBIT-marginaali−271,9%
+292,8 %-yks.v/v
Nettotulos−49,6milj. USD
+13,8 %v/v
Vapaa kassavirta−35,3milj. USD
−37,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−75−50−2502550milj. USD2020: 0,00 milj. USD2020: EBIT −20 milj. USD20202021: 0,59 milj. USD2021: EBIT −23 milj. USD20212022: 40 milj. USD2022: EBIT 18 milj. USD20222023: 19 milj. USD2023: EBIT −11 milj. USD20232024: 11 milj. USD2024: EBIT −62 milj. USD20242025: 14 milj. USD2025: EBIT −39 milj. USD202514−39
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Opus Genetics, Inc.

Liiketoiminta

Osuus liikevaihdosta
Gene therapy programs0 %

AAV-based therapies targeting inherited retinal disease mutations and other ophthalmic disorders.

Licensed ophthalmic product15 %

Phentolamine Ophthalmic Solution 0.75% marketed by a partner and generating royalties.

Small-molecule ophthalmology candidate0 %

APX3330, a Ref-1 inhibitor being developed for diabetic retinopathy.

License and collaboration revenue85 %

Milestones, reimbursements, and other non-product revenue from partners.

Asiakkaat

Opus primarily serves patients with inherited retinal diseases and other serious eye disorders through its development pipeline, while its commercial exposure comes indirectly through partners that market licensed products. Revenue today is tied mainly to collaboration counterparties and royalty-bearing arrangements rather than direct end-customer sales. The company’s future commercial customers would include retina specialists, ophthalmologists, and treatment centers if its pipeline products reach approval.

Rare disease patients and caregivers

Patients with IRDs, LCA, bestrophinopathy, or retinitis pigmentosa who would receive approved gene therapies or ophthalmic treatments.

Pharmaceutical and biotech partners

Licensees and collaborators that fund development, pay milestones, or commercialize partnered assets such as RYZUMVI®.

Eye care specialists

Retina specialists and ophthalmologists who would diagnose, refer, and prescribe if pipeline assets are approved.

Payers and health systems

Insurers and healthcare systems that would reimburse high-value ophthalmic therapies after approval.

Strategia

Opus is focused on advancing its gene therapy pipeline for inherited retinal diseases while maintaining partnered and licensed assets that can generate non-dilutive revenue. It also seeks collaborations, out-licensing, and potential in-licensing to broaden its ophthalmology portfolio and support development.

Advance gene therapy pipelineKeskipitkä aikaväli

Clinical progress is the main path to value creation in rare ophthalmic diseases.

Partner non-core assetsLyhyt aikaväli

Collaborations can reduce funding needs and keep programs moving without full internal commercialization.

Expand ophthalmology portfolioKeskipitkä aikaväli

Additional assets can diversify scientific risk and broaden the addressable market.

Monetize partnered productsLyhyt aikaväli

Royalties and milestones can provide non-dilutive support while pipeline assets mature.

Maantiede

Opus is headquartered in the United States and operates as a U.S. biopharmaceutical company, with development and partnering activity centered on ophthalmology programs. Its addressable market is global because inherited retinal diseases occur across U.S. and ex-U.S. patient populations, and the company’s licensing and commercialization opportunities can extend beyond the United States.

Riskit

Opus faces the typical risks of a clinical-stage biotech company: uncertain clinical outcomes, regulatory approval risk, and dependence on intellectual property protection. It also relies on collaborators, external funding, and successful manufacturing scale-up for gene therapy programs, any of which can delay development or reduce future revenue.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure or delay1Intellectual property protection risk2Collaborator dependence3Financing and dilution risk4Manufacturing and scale-up risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failure or delayVaikutus: KriittinenTodennäköisyys: Kohtalainen

    The pipeline is based on novel gene therapy and ophthalmic mechanisms with uncertain trial outcomes and timelines.

    KohdistuuLCA5BEST1RHOAPX3330
  2. Intellectual property protection riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The business depends on patents, licenses, and trademarks to protect product candidates and partner value.

    Kohdistuu: U.S. and foreign IP rights

  3. Collaborator dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Milestones, reimbursements, and commercialization may depend on third parties that can change priorities or funding.

    Kohdistuu: license and collaboration agreements

  4. Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    As a clinical-stage company, ongoing development requires external capital before product revenue is established.

    KohdistuuEquityDebtAlternative financings
  5. Manufacturing and scale-up riskVaikutus: KorkeaTodennäköisyys: Matala

    Gene therapies require specialized production capacity and quality control that can constrain trial execution and launch readiness.

    Kohdistuu: AAV-based programs

Kysy Clarifolta: Opus Genetics, Inc.

Kirjanpito

Harkinnanvaraiset erät
License and collaboration revenue recognition

Revenue may be recognized from upfront fees, milestones, reimbursements, and royalties at different times, affecting comparability.

Vaikutus: license agreements, Viatris-related revenue

Fair value of warrant and derivative liabilities

Changes in valuation assumptions can create non-cash gains or losses in the income statement.

Vaikutus: reported net loss volatility

Acquisition accounting and contingent consideration

The Opus acquisition and prior asset purchases can create intangible assets, liabilities, and future amortization or earn-out effects.

Vaikutus: balance sheet and future earnings

R&D expense estimation

Clinical and preclinical programs require judgment on accruals, external study costs, and timing of spend.

Vaikutus: research and development expense

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Ocugen, Inc.

OCGN · Biological Products, (No Diagnostic Substances)

RetinalGenix Technologies Inc.

RTGN · Surgical & Medical Instruments & Apparatus

Outlook Therapeutics, Inc.

OTLK · Biological Products, (No Diagnostic Substances)

Oculis Holding AG

OCS · Pharmaceutical Preparations

Ovid Therapeutics Inc.

OVID · Pharmaceutical Preparations

OS Therapies Inc

OSTX · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Opus Genetics, Inc. (IRD) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo